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Abstract
The molecular mechanisms determining transmissibility and prevalence of drug-resistant
tuberculosis in a population were investigated through whole genome sequencing of 1,000
prospectively-obtained patient isolates from Russia. Two-thirds belonged to the Beijing lineage,
which was dominated by two homogeneous clades. MDR genotypes were found in 48% of isolates
overall and 87% of the major clades. The most common rifampicin-resistance rpoB mutation was
associated with fitness-compensatory mutations in rpoA or rpoC, and a novel intragenic
compensatory substitution was identified. The proportion of MDR cases with XDR-tuberculosis
was 16% overall with 65% of MDR isolates harboring eis mutations, selected by kanamycin
therapy, which may drive the expansion of strains with enhanced virulence. The combination of
drug resistance and compensatory mutations displayed by the major clades confer clinical
resistance without compromising fitness and transmissibility, revealing a biological contribution to
the tuberculosis program weaknesses driving the persistence and spread of M/XDR-tuberculosis in
Russia and beyond.
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Introduction
Tuberculosis is the second leading cause of death from an infectious disease, after HIV. In
2011, there were an estimated 8.7 million new cases and 1.4 million deaths from the
disease1. The increasing prevalence of drug resistance is a major public health concern that
threatens progress made in controlling drug-sensitive tuberculosis2. Globally, 4% of new
cases and 20% of previously-treated cases are estimated to have multidrug-resistant (MDR)
tuberculosis, defined as resistance to at least rifampicin and isoniazid with the highest
proportions in Eastern Europe and Central Asia1. MDR cases require prolonged costly
treatment with toxic second-line drugs, and rates of treatment failure and mortality are
high2–4. Extensively drug-resistant (XDR) strains, which are MDR with additional
resistance to any fluoroquinolone and at least one of the second-line injectable agents
(kanamycin, amikacin or capreomycin), have now been found in every region of the world1.
Globally, the proportion of MDR-tuberculosis cases with XDR-tuberculosis has reached 9%.
In the UK, 26 XDR cases were reported between 1995 and 2011; 45% (9/20) of the patients
with known country of birth originated from Eastern Europe5. Recent years have seen an
ominous accumulation of reports of ‘totally’ drug-resistant strains, which are not susceptible
to any tested drugs6.
Prevalence of drug-resistant tuberculosis is dependent on the rate of acquisition of resistance
mutations (acquired resistance) and transmission of drug-resistant strains (primary
resistance). In Mycobacterium tuberculosis, drug resistance arises through chromosomal
mutation, typically resulting in a fitness cost seen as a reduced growth rate in vitro7. Fitness
cost generally inversely correlates with the mutation’s frequency in clinical isolates8.
Compensatory mutations mitigating the deleterious effect of resistance mutations are also
important in determining the transmissibility of specific genotypes9. Studies using molecular
epidemiological clustering rates to assess the transmission cost of resistance genotypes
report varying results10,11 suggesting that fitness costs may be affected by epistasis, that is
the phenotypic effect of a mutation depends on the presence or absence of other mutations in
the same genome12.
Whole genome sequencing (WGS) offers the power to track the evolutionary mechanisms
that promote development and transmission of drug resistance within pathogen populations
with unparalleled resolution. Evidence for adaptive selection in response to antibiotic
therapy can be found by identifying homoplasies (mutations arising independently multiple
times within a phylogeny) or loci that are the subject of frequent mutation13–15. By
identifying all changes that occur in a genome it is possible to uncover co-occurring
polymorphisms that contribute to resistance phenotypes or signify epistatic effects12.
The high incidence of MDR and XDR-tuberculosis in Samara3,16, a region of over three
million citizens in Russia, afforded the opportunity to study the emergence and spread of
antibiotic resistance within a population. In this prospective study, the largest of its kind yet
reported, we used WGS to investigate the molecular mechanisms of resistance, fitness
compensation and positive epistasis that together determine the transmissibility and
prevalence of drug-resistant strains. Comparative analysis of XDR isolates from the UK
addressed the origin of highly drug-resistant tuberculosis in this low-prevalence country.
Results
Population structure
During a two-year period (2008-2010), 2,348 M. tuberculosis isolates were prospectively-
collected from individual patients living in Samara, Russia. The genomes of 1,000 isolates
were sequenced. Comparison of patient epidemiological data indicated this sample was
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representative of the entire population and covered the distribution of tuberculosis patients
across the whole region (Figure 1, Supplementary Table 1). For comparison, we selected 28
sequences from a study of over 2,000 London-based tuberculosis patients, originating from
90 different countries, as representatives of the global population17,18. We included five
phenotypically-XDR strains isolated from UK-patients in 2011, as well as an isolate from
Estonia representing the clone that dominates the M. tuberculosis population of this
country19.
Mapping reads for each isolate against the reference sequence, H37Rv, revealed a total of
32,445 single nucleotide polymorphisms (SNPs) in non-repetitive regions of the genome,
including 238 associated with drug resistance. These variable sites were used to reconstruct
a maximum-likelihood phylogeny (Figure 2, Supplementary Data 1). Tree topology was
consistent with the global phylogenetic structure of M. tuberculosis sensu stricto comprising
four main lineages20,21. Of the 1,000 Samaran isolates, 642 belonged to the Beijing lineage,
355 to the EuroAmerican lineage, two to the CAS lineage and a single isolate to the EAI
lineage, reflecting the proportions seen in the whole patient population.
In comparison to the disparate Beijing isolates from the UK, the majority of Samaran
Beijing sequences formed a monophyletic group, we term the ‘East European’ sublineage18
(Supplementary Figure 1), consistent with a single relatively recent expansion of this lineage
in the region. Bayesian population genetic clustering22 defined the two largest clades nested
within the Beijing lineage: clade A and clade B, comprising 264 and 119 isolates,
respectively (Supplementary Figure 2). In addition to these clades, the majority of other
Beijing isolates were members of smaller clusters; 60% (387/642) of all Beijing isolates
differed from their last common ancestor by five or less SNPs (Supplementary Figure 3).
The Western part of Samara is geographically-isolated by the River Volga. Comparison of
the isolate population in the West to the rest of the region revealed a significant reduction in
the proportion of clade A (18% vs 28%, p=0.04; Supplementary Table 2, Supplementary
Figure 4).
The EuroAmerican lineage showed a significantly higher nucleotide diversity (π=0.0042,
SD 0.00018, 95% CI 0.0038-0.0045) than the Beijing lineage (π=0.0022, SD 0.00039, 95%
CI 0.0015-0.0030). Fewer EuroAmerican isolates were members of closely-related clusters;
39% (137/355) differed from their last common ancestor by five or fewer SNPs (p<0.001).
Although, global diversity within the EuroAmerican lineage is not yet well characterized,
Homolka et al.23 identified eight SNP-based sublineages that were broadly concordant with
molecular fingerprint-based classification. We identified four of these sublineages in Samara
(Haarlem, LAM, Ural and S-type), whilst 36% isolates could not be classified by this
scheme (Figure 2).
Short genetic distances between isolates have been used to infer the likelihood of direct
transmission24. In this dataset, four pairs of patients with sequenced isolates shared
households. Within three households the patient isolates were almost identical with zero,
two and three SNPs separating each pair, consistent with intra-household transmission or
infection from a common source24. Patients in the fourth household were infected with
unrelated isolates (183 SNPs difference). In addition to the household pair, 30 further pairs
of isolates, three clusters of three isolates and one cluster of five isolates had zero SNP
differences. Patients with identical isolates were resident in the same region of Samara in
only 20 of these 35 clusters. Mapping addresses revealed that patients with identical strains
lived up to 136km apart (Supplementary Figure 5).
XDR-tuberculosis isolates from four UK patients, who originated from the Baltic States,
were members of the East European sublineage with two belonging to clade B and one to
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clade A, suggesting that infections may have been acquired during stays in their country of
origin or within sympatric communities in the UK (Figure 2). In support of this conjecture,
the fifth XDR isolate, from a Chinese patient, was not a member of the East European
sublineage. The Estonian isolate was also member of clade B. Correlation of VNTR
fingerprint data indicated that this is the same strain that predominates across Northwestern
Russia18,19,25. The East European isolates were remarkably closely-related with isolates
from different countries separated by as little as 13 SNPs (Supplementary Table 3).
Prevalence of MDR genotypes
A maximum-likelihood phylogeny of the 1,000 Russian isolates was reconstructed and
illustrated with drug resistance genotypes (Figure 3, Supplementary Tables 4-6). The most
commonly mutated drug resistance locus, katG codon 315, which confers high-level
resistance to isoniazid26, was substituted in 74% (478/642) of Beijing isolates and 30%
(106/355) of EuroAmerican isolates (p<0.001; Figure 4, Supplementary Table 7). A novel
nonsense SNP at codon 668 also mediated resistance, consistent with the requirement of
KatG for activation of the pro-drug. All (478) of the Beijing katG mutants carried the S315T
substitution, whilst 11% (12/106) of EuroAmerican isolates harbored one of three alternative
substitutions in codon 315 (p<0.001).
A total of 70 isolates had mutations in the promoter of the fabG1-inhA operon, which confer
low-level cross-resistance to isoniazid and its structural analogs, ethionamide and
prothionamide27. Based on phylogenetic reconstruction, for 44 isolates the inhA mutation
arose in a katG mutant. It is improbable that isoniazid therapy would select for mutations
conferring low level resistance in the presence of a high-level resistance SNP indicating that
the majority of these promoter SNPs were acquired in response to ethionamide/
prothionamide therapy.
Mutations within the 81bp rifampicin resistance-determining region (RRDR) of rpoB are
accurate predictors of rifampicin resistance in M. tuberculosis28. Within this region we
identified 20 non-synonymous SNPs (nsSNPs) and two small deletions, which affected 70%
(430/642) of Beijing and 19% (67/355) of EuroAmerican isolates (p<0.001). The most
common rifampicin-resistance genotype, S450L, was found in 90% (390/435) of Beijing
isolates with RRDR mutations and 67% (45/67) of EuroAmerican isolates (p<0.001).
Based on these genotypes, 66% (422/642) of Beijing and 17% (61/355) of EuroAmerican
isolates have a predicted MDR phenotype (p<0.001). The proportion of isolates that were
MDR in clades A and B was significantly higher than for the rest of the Beijing lineage
(332/383 vs 90/259, p<0.001).
Compensatory mutations in MDR isolates
We investigated the occurrence of compensatory mutations in RpoA and RpoC18 in isolates
carrying rifampicin-resistance mutations. We identified 14 different nsSNPs in rpoA, 11 of
which were found in isolates containing the rpoB S450L mutation (equivalent to
Escherichia coli S531L), emerging significantly more frequently in this genetic background
(16/435 vs 4/565, p=0.001). Mutations in the most commonly substituted residue, T187,
were acquired independently at least seven times, providing strong evidence that rpoA is the
subject of positive selection pressure. Clustering of SNP sites within three small regions
suggesting these sites are important for interaction with the rifampicin-binding pocket
(Figure 5). Eighteen of the 58 nsSNPs identified in rpoC were homoplasic. The rpoC
nsSNPs were significantly more likely to arise in isolates harboring RpoB S450L than those
with WT RRDR or other resistance mutations (76/435 vs 11/565, p<0.001; Supplementary
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Table 8). In total, 36 of the 59 amino acid substitutions in RpoA or RpoC found associated
with the mutation RpoB S450L have not been previously reported18,29.
Overall, 47% (170/390) of isolates containing the S450L mutation had a putative
compensatory mutation in rpoA or rpoC. However, they were remarkably infrequent in
clade A (Figure 3, Supplementary Figure 6); 89% (150/169) of non-clade A Beijing isolates
harboring S450L had an nsSNP in rpoA or rpoC, compared to 9% (20/221) of clade A
isolates (p<0.001). This was unexpected given the obvious epidemiological success of this
clade. Thus, we predicted that the large distal cluster of clade A isolates carrying RpoB
S450L harbored alternative compensatory mutations that restored fitness. By inspection of
the phylogeny we deduced the branch on which this putative mutation likely occurred; one
of the four SNPs on this branch resulted in the RpoB substitution E761D (Supplementary
Figure 6). Intragenic compensatory mutations in rpoB harboring resistance mutations have
been observed in experimentally-evolved E. coli30, Pseudomonas aeruginosa31 and
Salmonella enterica32. We surmise that the E761D substitution provides an analogous
fitness benefit in M. tuberculosis strains carrying rpoB S450L.
In addition to the E761D substitution and excluding RRDR polymorphisms, a further 26
nsSNPs were identified in rpoB. Sixteen of these co-occurred with S450L (Figure 5) and
were significantly more likely to be found in isolates without alternative compensatory
mutations (24/37 vs 2/396, p<0.001). Multiple substitution events in codons 496 and 835
provide affirmation that regions of rpoB other than RRDR are under selective pressure.
Including all putative compensatory SNPs, 97% (421/435) of isolates carrying rpoB S450L
harbored additional rpoABC mutations, which did not appear in any isolates with wild-type
RRDR and may mitigate the deleterious effect of this resistance mutation.
Sherman et al.33 proposed that loss of catalase-peroxidase function, in isoniazid-resistant
KatG mutants, was compensated by upregulation of alkyl hydroperoxidase, AhpC. We
identified four polymorphic sites within the ahpC regulatory region, including two
homoplasies. Of nine isolates harbouring the ahpC SNPs, four carried KatG S315T, four had
a rare mutation (S315G or W668*) and one had wild-type katG. The ahpC SNPs were
significantly more likely to arise in isolates with unusual katG mutations (2/12 vs 3/572,
p=0.004), supporting the theory that S315T has low or no fitness cost34.
Prevalence of XDR genotypes
We ascertained that 17% (71/422) of Beijing MDR and 7% (4/61) of EuroAmerican MDR
isolates had genotypes predicting an XDR phenotype (p=0.046).
Mutations in the eis promoter that confer kanamycin resistance35 were found in 66%
(317/483) of all MDR isolates. Eight different sites were polymorphic, including five
homoplasies. The eis mutations were significantly more common in isolates belonging to
clades A or B compared to the rest of the Beijing lineage (275/332 vs 21/90, p<0.001).
Mutations in the drug target, rrs, which confer resistance to amikacin and capreomycin, as
well as kanamycin36, were found in only 40 isolates, four of which had a pre-existing SNP
in the eis promoter.
Fluoroquinolones target the DNA gyrases, GyrA and GyrB, and resistance is conferred by
mutations within the quinolone resistance-determining regions (QRDRs) that interact with
the drugs37. Eighty-six isolates harbored mutations within the QRDR of gyrA and 11 Beijing
isolates had SNPs within the gyrB QRDR. Substitutions in gyrAB arose relatively more
often in isolates with rrs mutations than those with eis promoter mutations (15/40 vs 62/317,
p=0.009; Supplementary Figure 7).
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In addition to those isolates with fluoroquinolone-resistant genotypes, we noted a significant
number of isolates with ambiguous basecalls within the QRDRs (Supplementary Table 9).
This phenomenon was almost never observed at other drug resistance loci. For 18 isolates
with ambiguous gyrA genotypes, ambiguity was often apparent at more than one of the
codons (90, 91 and 94) that most commonly confer resistance (Supplementary Figure 8).
Inspection of raw sequencing reads mapping to this region revealed that substitutions did not
co-occur on a single read, indicating multiple fluoroquinolone-resistant clones co-existed in
the patient. Fluoroquinolone-treatment of non-tuberculosis infections with could drive
acquisition of fluoroquinolone-resistance in chronically-infected tuberculosis patients38. In
this case, we would expect to see resistance in non-MDR isolates; however, we found no
resistant or heterogeneous QRDR genotypes in non-MDR isolates indicating that the
fluoroquinolone exposure was tuberculosis therapy.
Adaptive selection at other drug resistance loci
Repeated independent acquisition of SNPs, revealed by phylogenetic homoplasy, provides
strong evidence of selection13 (Supplementary Table 10). Farhat et al.14 recently identified
22 genomic regions that were novel targets of positive-selection in drug-resistant strains
(excluding those in repetitive regions) including four that harbored homoplasies in our
dataset. Using a complementary approach, Zhang et al.15 identified 98 novel regions that
were enriched for SNPs in drug-resistant versus drug-sensitive strains, including 11 where
we identified homoplasies.
EmbB harbored homoplasic mutations at codons 306, 406 and 497 that are commonly
associated with ethambutol-resistance, although discordance with susceptibility testing is
reported39. Homoplasic mutations were identified in five further embB codons (Table 1).
Surprisingly, the most frequent homoplasic embB substitution was D354A, which affected a
large cluster of clade A isolates, plus two unrelated isolates. This unusual mutation was
associated with phenotypic ethambutol resistance in 50% (83/166) of isolates tested.
Multiple SNP acquisitions in the region upstream of embAB provide evidence that operon
upregulation also confers resistance40. Promoter and coding SNPs frequently co-occurred;
isolates with two mutations were more often phenotypically resistant (27/28 vs 199/375,
p<0.001; Supplementary Table 5) offering an explanation for the poor concordance between
embB 306 mutations and phenotypic resistance39.
The pyrazinamide resistance gene, pncA41, was the most variable gene in the genome (Table
2, Supplementary Figure 9). In addition, it’s promoter harbored five different mutations.
GidB was the second most polymorphic gene, indicating that it is a target of selective
pressure and supporting its proposed role in streptomycin-resistance42. Discounting the
common sublineage-defining SNPs43, gidB mutations were relatively more common in
EuroAmerican versus Beijing isolates (47/355 vs 16/642, p<0.001) and were less likely to be
concomitant with rpsL or rrs (1/47 vs 13/16, p<0.001). This skewed distribution suggests
gidB mutations have a lineage-specific effect. EthA, which catalyzes activation of the pro-
drug ethionamide44, was also amongst the most highly-variable genes in the population. A
homoplasic SNP 7bp upstream of ethA was independently acquired at least twice, both times
in clade A. Positive selection of this SNP suggests it functions clinically in resistance,
though only 33% (56/172) of the promoter mutants tested phenotypically resistant. In total,
84% (409/483) of all MDR isolates carried mutations in ethA or it’s upstream region.
Transmissibility of drug resistance
Previous studies relied upon fingerprint clustering to estimate the transmission dynamics of
drug resistance genotypes10,11. Employing a similar principle, but with the improved
resolution of WGS, we investigated transmissibility by using the phylogeny to estimate the
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number of isolates that independently acquired a SNP versus the number of isolates that
inherited that SNP from an inferred common ancestor, indicating primary resistance.
SNPs conferring resistance to rifampicin, isoniazid, streptomycin and ethambutol were
significantly more likely to be found in phylogenetic clusters, than not (p<0.05; Figure 6,
Supplementary Table 11). By inferring the order of SNP acquisition events from the
phylogenetic tree, we determined that for 97% (481/495) of isolates with RRDR SNPs a
mutation in KatG S315 occurred prior to or on the same branch as the RRDR SNP. Hence,
phylogenetic clustering of rpoB SNPs is essentially a surrogate for clustering of MDR
genotypes.
Pyrazinamide-resistance genotypes were the most often acquired; the modal number of
isolates harboring each pncA coding or promoter polymorphism was one (65 of 106 clusters)
and only one mutation was shared by a phylogenetic cluster of more than seven isolates. The
common pncA nsSNP, encoding the conservative substitution I6L, was found in 157 clade A
isolates. This SNP was not associated with phenotypic pyrazinamide resistance in vitro
(Supplementary Table 5), however, no secondary pncA mutations were identified in these
isolates.
SNPs in gyrA were significantly less likely to be found in clusters (p=0.006; Supplementary
Table 11); the largest cluster contained five isolates and 59% (52/88) of resistant isolates did
not cluster. In contrast, eis promoter SNPs were typically found in large clusters, the most
notable a cluster of 207 clade A isolates.
Discussion
In the largest bacterial WGS project reported to date, we provide a region-wide snapshot of
the M. tuberculosis population in Samara, Russia. Circulating strains belonged mainly to
two lineages: Beijing and EuroAmerican. In concordance with other Russian-based studies,
the Beijing lineage was dominant and accounted for two-thirds of isolates16,25. Relative to
the Beijing lineage, EuroAmerican isolates were phylogenetically-diverse and the tree
topology supports the division of this lineage into multiple sublineages23. Samaran Beijing
isolates were essentially monophyletic with respect to isolates representing the global
population, forming a group we term the East European sublineage, which was dominated
by two clades of extremely limited diversity. Short genetic distance between tuberculosis
isolates has been used to infer transmission links24. In this population, we found large
geographic distances within even identical clusters suggesting that they did not always
reflect transmission events or that the importance of casual contact may be underestimated.
Genotypes conferring drug resistance were extremely common; 48% of isolates had an
MDR genotype and 16% of these were XDR. In comparison to a small microbiologically-
based study conducted in Samara in 200145, the proportion of MDR isolates resistant to
amikacin has remained relatively stable (7.2% vs 8.5%) whereas the frequency of
fluoroquinolone resistance has risen substantially from 4.3% to 23.8%. However,
fluoroquinolone resistance was significantly more likely to be acquired than other resistance
genotypes indicating that gyrAB mutants may have impaired transmission fitness, impeding
the spread of XDR clones. Current rates of resistance support the continued use of
fluoroquinolones plus amikacin or capreomycin, rather than kanamycin, for MDR therapy.
Whilst a fluoroquinolone plus prothionamide had high efficacy for MDR treatment in
Lithuania, which has a comparable MDR-tuberculosis problem and similar historical
treatment strategy4, the frequency of ethA mutations in Russian isolates means thioamides
may be ineffective in this population.
Casali et al. Page 7
Nat Genet. Author manuscript; available in PMC 2014 September 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Drug resistance has previously been associated with the Beijing lineage16. Here we provide
evidence that Beijing isolates were more likely to harbor the isoniazid-resistance genotype,
katG S315T, that has a negligible fitness cost34 and the rifampicin-resistance genotype, rpoB
S450L, that we find strongly associated with putative compensatory mutations within the
RNA polymerase genes. Other studies have shown that rpoC mutations restored fitness in
competitive growth assays29 and were significantly more common in isolates belonging to a
fingerprint-cluster than in non-clustered isolates9. These observations explain, at least in
part, the predominance of Beijing MDR isolates. The widespread use of kanamycin in MDR
therapy may further exacerbate spread of MDR strains by selecting strains with eis
mutations that both confer resistance35 and increase bacterial multiplication in host
macrophages46 by disrupting the protective immune response47. Interestingly, eis mutations
were significantly associated with the dominant Beijing clades.
The epidemiological success of clade A was particularly striking and the ‘comb-like’
structure of the tree, apparent in the distal portion of the clade, suggested a highly-infectious
clone. The incomplete dispersion of clade A to Western Samara supports its recent and rapid
spread. From this we deduced the presence of unidentified fitness-enhancing mutations,
which led to the discovery of novel intra-rpoB compensatory mutations associated with
rifampicin-resistance. In addition, we surmised that a novel SNP upstream of ethA likely
confers low-level clinical ethionamide resistance, not detected in vitro, through promoter
disruption or enhanced binding of the EthR repressor48. Typically, the most common drug
resistance SNPs are associated with the least fitness cost8 implying that successful clones
would carry these SNPs. Thus, the discovery of this novel ethA promoter SNP and the rare
embB nsSNP D354A, in clade A was unexpected.
The majority of clade A isolates had a conservative I6L substitution in the pyrazinamide-
resistance gene, pncA, which does not confer resistance in vitro and is the only pncA nsSNP
found in a large cluster. The deduced frequency of acquired pyrazinamide resistance in the
sequenced population, plus the small cluster size associated with primary resistance,
suggests that mutants with non-functional PncA have impaired transmission efficiency.
Given the prevalence of pyrazinamide resistance in the population, it is difficult to reconcile
the epidemiological success of clade A with a pyrazinamide-sensitive phenotype. We
speculate that the I6L substitution results in intermediate PncA activity that manifests as
pyrazinamide sensitivity in vitro but clinical resistance in vivo, and retains sufficient
nicotinamidase activity for efficient transmission.
We propose that the unusual combination of drug resistance and compensatory mutations
acquired by clade A comprise a ‘perfect storm’ providing clinical drug resistance without
compromising fitness and transmissibility.
Preventing tuberculosis transmission relies on accurate and rapid diagnosis. Molecular
methods that reduce the time taken to detect drug-resistant tuberculosis strains expedite the
institution of effective therapy and efficient infection-control measures, thus minimizing the
infectious period. WGS offers the potential for rapid unambiguous determination of all
existing, clinically-significant drug resistance mutations and the reducing costs have
neutralized a major argument over the value of targeted sequencing versus WGS. We have
reported the existence of double mutations at some resistance loci, as well as the lineage-
and clade-specific association of certain mutations which are suggestive of undiscovered
epistatic interactions. These observations indicate that drug-resistance may be more multi-
factorial than previously appreciated which, in some cases, may explain discordance
between phenotypes and genotypes. As more resistance loci are identified, and the
phenotypic effects of multiple mutations and strain background are elucidated, the public
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health value of routine WGS for diagnosis of drug resistance will increase, although it may
vary depending on the prevalence and likely exposure to resistant strains.
We have reported, with others, the extensive prevalence of MDR Beijing isolates in Russia
and former Soviet states of Eastern Europe1,4,16, which shared a common treatment and
BCG vaccination strategy. In addition to programmatic and clinical weaknesses, we have
identified plausible biological explanations contributing to the devastating MDR-
tuberculosis situation in the region. The current dominance of clade B across Eastern
Europe19,25 and the isolation of both clade B and clade A in the UK, indicate that the
situation throughout the European Union could follow that in the East.
Methods
Study population and whole genome sequencing
From October 2008 to 2010, 2,348 patients with pulmonary disease and culture-proven
tuberculosis were recruited from all 18 civilian tuberculosis dispensaries located across
Samara. M. tuberculosis isolates were prospectively archived at the Samara Tuberculosis
Service, Samara, Russia. Anonymized epidemiological data was stored on a password-
protected ACCESS database. Informed consent was obtained from all patients. The study
was approved by the Samara Medical Ethics Committee, the Queen Mary Research Ethics
Committee and the University of Cambridge Research Ethics Committee.
Isolates were cultured on Middlebrook media for 4–6 wk at 37°C. Sweeps of colonies were
harvested, lysed by vortexing with glass beads and genomic DNA purified using a DNeasy
Blood and Tissue kit (Qiagen). Paired-end multiplex libraries with a mean insert size of
200bp were prepared as previously described50. Sequencing was performed at the Wellcome
Trust Sanger Institute on the Illumina Genome Analyzer GAII or the HiSeq 2000 platform
generating reads of 54-bp, 75-bp or 100-bp.
Sequence analysis
Sequence reads were aligned to the corrected H37Rv reference genome18,51 with SMALT
(see URLs) and GATK indel realignment applied52. Pindel53 was used to predict the
positions of indels and structural variants; these were visually checked in the mapping files.
Candidate SNPs were identified using SAMtools54. At each mapped position, alleles were
considered to be valid if supported by greater than 70% of mapped reads, including at least 5
in each direction and a minimum mapping quality of 45. SNPs located within repetitive
regions were excluded from analysis18.
Mixed basecalls in non-repetitive regions of the genome were considered valid if mapping
quality was ≥45, both calls were supported by at least five reads on each strand, and P-
values for strand bias, base quality bias, map quality bias and tail distance bias were ≥0.001.
To assess data consistency, nine isolates that were sequenced with 54-bp paired-end reads
were re-cultured and 100-bp paired-end sequence generated. For each of these technical
replicates, there were no inconsistencies in bases called at variant sites that passed quality
filters in both sequences.
Phylogenetic and population genetic analyses
A maximum likelihood phylogeny was reconstructed with RAxML55 using a general time-
reversible model with gamma correction for among site rate variation. Calculation of 100
bootstrap replicates provided support for nodes on the tree. The phylogenetic tree was
visualized with FigTree (see URLs tree.bio.ed.ac.uk/software/figtree). Ancestral sequences
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were reconstructed onto each node of the phylogeny using PAML56. From these ancestral
sequences, SNPs were reconstructed onto branches of the tree.
To statistically define the population structure we used the software BAPS (Bayesian
Analysis of Population Structure)57,58, in particular its module hierBAPS22, which
delineates the population structure using nested clustering. Three nested levels of molecular
variation were fitted to the data using 10 independent runs of the stochastic optimization
algorithm with the a priori upper bound of the number of clusters varying over the interval
50-300 across the runs.
To estimate the nucleotide diversity π59 for the EuroAmerican and Beijing clades, the
functions available in the PGEToolbox60 were used in parallel on a cluster computing
environment. The very large number of sequences in each clade would require excessive
amounts of computing resources when analyzing all the sequences in a single process, and
hence, to allow for more economical calculations, 50 random subsets of 100 strains were
sampled from each clade and the inference was performed by using 100 bootstraps for each
of them, as described by Cai et al.60, and averaging the results. Confidence intervals for the
π estimates were computed using the normal distribution approximation with the standard
deviation derived by the bootstrap procedure.
Molecular fingerprinting and microbiological testing
Isolates were characterized by spoligotyping according to standard methods61.
Susceptibility to the first-line drugs rifampicin, isoniazid, streptomycin, ethambutol and
pyrazinamide was determined using the absolute concentration method on Lowenstein-
Jensen slopes62 or using the automated Mycobacterial Growth Indicator Tube (MGIT) 960
system (Becton Dickinson)63. For MDR isolates, susceptibility to the second-line drugs -
amikacin, capreomycin, ofloxacin, moxifloxacin and prothionamide - was also determined
using the MGIT system61.
A quality assurance procedure was implemented to ensure that isolate metadata
corresponded to the appropriate sequence. Data for isolates belonging to the SNP-defined
Beijing lineage that did not exhibit the characteristic Beijing spoligotype and, conversely,
isolates in other SNP-defined lineages that shared the Beijing spoligotype were excluded
from further analysis (n=45). The specificity of katG S315T for prediction of isoniazid
resistance is >99%64; thus, microbiological data for isolates with this genotype but a
sensitive phenotype were also excluded (n=58).
Statistical methods
Simple descriptive statistics were used to compare the sample population patient data with
the remaining population and to characterize the prevalence of mutations and geographic
distribution of sublineages; 95% confidence intervals (SD) were established. In addition, the
sampled population was evaluated by attributive risk analysis. The significance of
differences between studied groups of variables was calculated using two-sample tests of
proportions: Pearson chi-square or Fisher’s exact test when any expected group size was less
than 5. Statistical tests were two-sided at α=0.05. The analysis was done using STATA
(version 12.1, StataCorp).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Coverage of the tuberculosis patient population
The location of Samara Oblast in Russia (red) and the Baltic States (Lithuania (Li), Latvia
(Lv) and Estonia (E)) are shown in (a). The number of sequenced patient-isolates from each
territory (green) and city (blue; Samara City (Sm), Togliatti (T) and Syzran (Sz)) of Samara
Oblast (b) or district of Samara City (c) are shown inside circles. The area of each circle
reflects coverage of the region (the number of isolates sequenced relative to the number of
tuberculosis cases notified).
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Figure 2. Maximum likelihood phylogeny of 1,035 M. tuberculosis isolates based on 32,445
variable sites
The four M. tuberculosis lineages: Beijing, CAS, EuroAmerican and EAI, are indicated. The
EuroAmerican SNP-defined sublineages23 and the major Beijing clades are shaded. The
ancestral node of the Beijing East European sublineage is indicated with a star. Radial dotted
lines show the positions of isolates from the UK; those with an XDR phenotype are marked
with white circles. The Estonian strain is indicated by a filled blue circle. The position of the
reference sequence, H37Rv, is marked ‘R’. The East European sublineage, Clade A and
Clade B had 100% bootstrap support (Supplementary Data 1).
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Figure 3. Phylogenetic distribution of drug resistance and compensatory genotypes
The phylogeny of 1,000 Russian isolates is depicted on the left; lineages are colored as
Figure 2. The first 16 columns depict drug resistance loci. ‘P’ denotes a promoter region.
Within the 16S rRNA gene, rrsstr refers to the 530 stem-loop and 915 regions involved in
streptomycin resistance49 and rrsinj to downstream regions associated with resistance to the
second-line injectables36. Colored bands represent different polymorphisms and include
previously identified and novel mutations described in the text. The last three columns show
nsSNPs in the RNA polymerase genes, rpoABC, excluding those shown in the RRDR. The
genotypes illustrated are provided in full in Supplementary Table 4.
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Figure 4. Prevalence of drug resistance mutations and association with lineage
The proportion of isolates harboring polymorphisms at each drug resistance locus was
categorized by lineage. Asterisks indicate significant differences between lineages
(Supplementary Table 7). Data is based on the polymorphisms detailed in Supplementary
Table 4.
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Figure 5. Distribution of rifampicin resistance and compensatory amino acid substitutions in the
RNA polymerase genes, rpoBCA
Resistance mutations are clustered in the RRDR region of rpoB. All other substitutions
depicted are putative compensatory mutations that co-occurred with rpoB S450L.
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Figure 6. Transmissibility of drug resistance genotypes
The number of isolates within clusters sharing a genotypic marker was estimated by
maximum likelihood reconstruction of the polymorphisms onto the phylogeny. A cluster
size of one suggests acquired resistance while larger clusters are indicative of primary
transmitted resistance.
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Table 1
Ethambutol resistance mutations
Locus Substitution Reference SNP
Number of
isolates
Number of
acquisitionsb Additional mutationsc
PembAB −16 C T/A/G 15/7/1 9/3/1 M306I(4); D354(6)
−15 C G 1 1 -
−12 C T 9 8 M306V(1); D354(2); Q497R(1)
−11 C A 1 1 -
−8 C A 7 1 D354(7)
embB M306Va/La A G/C 114/4 29/2 −12(1); D354(2)
M306Ia G A/C/T 23/18/11 14/9/2 Q497R(4); −16 (4)
Y319S/C A C/G 3/3 1/2 -
D354A A C 213 3 −8(7); −12(2); −16(6); M306V(2)
E378A A C 2 2 -
G406Da/A G A/C 16/16 6/4 -
Q497K C A 9 3 -
Q497Ra A G 27 11 −12(1); M306I(4)
H1002R A G 3 3 -
D1024N G A 3 2 -
a
High confidence mutation in TB Drug Resistance Mutation Database (see URLs)
bNumber of times the mutation independently arose
cNumber of isolates with additional mutation is given in brackets
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Table 2
Mutations in highly-polymorphic genes implicated in drug resistancea
Locus
Drug
resistance
Gene
length
(bp) nsSNPs
Nonsense
SNPs Indels b
Large
deletions
pncA pyrazinamide 561 79 1 16 5
gidB streptomycin 675 28 2 9 1
ethA ethionamide 1470 33 6 19 2
a
Determined by calculating the number of nsSNPs per gene, adjusted for length
b
all indels resulted in frameshifts
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